Zoetis Enhances Librela Label for Canine Osteoarthritis Treatment
Zoetis Inc. has recently made significant strides in its quest to improve the lives of dogs suffering from osteoarthritis (OA) pain by updating the U.S. label for Librela (bedinvetmab injection). This initiative comes after the company submitted a supplement to the U.S. Food and Drug Administration (FDA), reflecting data gathered over the past year since Librela's introduction into the market.
Commitment to Quality and Safety
Following the launch of Librela, Zoetis remains steadfast in its commitment to both veterinarians and pet owners. The FDA-approved Librela provides an effective solution for managing OA pain in dogs, having already helped treat over a million canines across the United States. With a focus on transparency, Zoetis has bee n in continual discussion with the FDA, providing updates on real-world experiences to assure quality and efficacy.
Real-World Impact of Librela
Launched four years ago in Europe, Librela offers a once-monthly injectable treatment option that has positively impacted the lives of millions of dogs suffering from OA pain. With nearly 25 million doses distributed globally and a reassuring safety profile—showing minimal adverse events—the product emphasizes Zoetis's dedication to providing effective treatment options.
Expert Insights on Canine OA Treatment
Dr. Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer of Zoetis, emphasizes the importance of communication between pet owners and veterinarians. He notes that while treatments like Librela offer significant benefits, understanding both potential risks and advantages is paramount for ensuring the best outcomes for canine companions.
Resources for Veterinary Practices
Immediate access to the updated Librela label and Client Information Sheet will be made available on Zoetis's website, where veterinarians can easily download the materials. This underscores Zoetis's proactive approach in equipping veterinary practices with the necessary tools and information to support their work.
Educational Support Initiatives
Zoetis has consistently invested in educational initiatives for veterinarians, hosting over 1,000 medical training webinars this year alone. These resources are designed to enhance the understanding of pain management in osteoarthritis and improve the overall veterinary practice. Additionally, dedicated 'office hours' with Dr. Goldstein enable veterinarians to address any critical questions directly.
About Librela
Librela is a revolutionary monoclonal antibody therapy that is effective in managing canine OA pain by targeting nerve growth factors. Unlike traditional treatments, it is administered in low doses within clinical settings, promoting a higher safety profile through natural metabolic pathways, making it a well-tolerated option for dogs.
About Zoetis
As a foremost leader in the animal health industry, Zoetis is focused on elevating the health and welfare of animals globally. With over 70 years of innovative solutions, the company's portfolio contains numerous medicines, vaccines, and diagnostics that enhance the care provided to animals and their caretakers worldwide. Their significant achievements in 2023 include generating revenue of $8.5 billion and employing approximately 14,100 workers dedicated to animal health.
Frequently Asked Questions
What is the purpose of the updated Librela label?
The updated Librela label aims to provide veterinarians and pet owners with enhanced information based on real-world experience to optimize treatment for canine osteoarthritis.
How does Librela work to alleviate OA pain in dogs?
Librela is a monoclonal antibody that targets nerve growth factors, effectively reducing pain associated with osteoarthritis in dogs.
What support does Zoetis offer veterinarians regarding Librela?
Zoetis provides resources such as updated labels, educational webinars, and direct communication channels with medical experts to support veterinarians.
How many dogs have been treated with Librela?
Over one million dogs have benefitted from Librela since its launch in the U.S., showcasing its positive impact on canine health.
What is the safety profile of Librela?
Librela has been shown to have a minimal rate of adverse events, reinforcing its safety and efficacy for canine patients undergoing treatment for osteoarthritis.
